ArchivePsoriasis is a chronic, recurrent, immune-mediated systemic inflammatory skin disease that significantly impairs patients' physical and mental health as well as the quality of life of patients. With the widespread application of treatment methods such as biological agents, the therapeutic effect of psoriasis has significantly improved, but the problem of recurrence remains prominent. Immune abnormalities (such as tissue resident memory T cells, cytotoxic T cell 17), genetic susceptibility, infectious factors, environmental changes, and unhealthy lifestyles are important triggers for psoriasis recurrence. Meanwhile, there are differences in the recurrence time of different types of biologics after discontinuation, and the risk of recurrence is closely related to patient's compliance and comorbidity status. The article systematically reviewed the relevant mechanisms, influencing factors, and intervention strategies for psoriasis vulgaris recurrence, and proposed multidimensional prevention and intervention strategies for recurrence issues, including optimizing biological agent management, combination therapy regimens, improving lifestyle, and long-term follow-up mechanisms, providing reference for clinical treatment.
Vitiligo is a common acquired skin mucosal pigment loss disease, and there is no cure. The pathogenesis of vitiligo is complex, involving multiple factors such as genetics, autoimmunity, and oxidative stress. With the deepening research on the pathogenesis of vitiligo, biologics targeting specific sites have been continuously developed, especially targeted treatments for immune regulation and anti-inflammatory response, which provide new ideas for the treatment of vitiligo. This article focused on the feasibility of using biologics as a new treatment method for vitiligo, in order to provide reference for exploring better treatment options.
Atopic dermatitis (AD) is a common chronic inflammatory skin disease that seriously affects the quality of life of patients. Traditional treatments such as topical steroids and immunosuppressants have limited efficacy in some patients and are accompanied by adverse reactions. In recent years, biologics have provided new treatment options for patients with moderate to severe AD by targeting key inflammatory factors. Dupilumab, as the first approved biologic, significantly improved patients' skin symptoms and pruritus. Subsequently, drugs such as tralokinumab, lebrikizumab, and nemolizumab further expanded the options for targeted therapy. Biologics have shown promising prospects in improving the treatment outcomes of patients with moderate to severe AD, and are expected to further improve efficacy and affordability through personalized medicine, optimized dosing strategies, and cost control. This article reviewed the targets, mechanisms of action, and clinical research progress of major biological agents, in order to provide reference for the clinical treatment of AD patients.
To explore the influence of ciprofol on anesthetic effect and vital signs of patients undergoing hysteroscopy.
A total of 114 patients who underwent hysteroscopic surgery under general anesthesia from January 2023 to October 2024 were selected and randomly divided into a control group and a study group, with 57 cases in each group. The control group received anesthesia induction and maintenance with propofol injection, while the study group received ciprofol injection. The vital signs, disappearance time of eyelash reflex, wake up time, orientation recovery time and occurrence of adverse reactions were compared between the two groups.
Before anesthesia, there was no statistically significant difference in heart rate (HR), peripherals oxygen saturation (SpO2), and mean arterial pressure (MAP) between the two groups (P>0.05). After anesthesia induction and at recovery, the MAP, SpO2 and HR in both groups decreased first and then increased, and the MAP and SpO2 in the study group were higher than those in the control group (P<0.05), and the wake up time of the study group was longer than that of the control group (P<0.05).There was no statistically significant difference in the disappearance time of eyelash reflex and the orientation recovery time between the two groups (P>0.05). The incidence of adverse reactions in the study group was lower than that in the control group (3.51% vs. 14.04%, P<0.05).
Ciprofol has a good anesthetic effect on patients undergoing hysteroscopic surgery. It can effectively maintain the stability of vital signs during and after the operation, and the incidence of adverse reactions is low.
To observe the clinical efficacy of Bushen Huoxue decoction in treating carotid atherosclerosis (CAS) with kidney deficiency and blood stasis, and its influence on blood lipid, inflammation, complement activation and carotid ultrasound.
A total of 90 CAS patients with kidney deficiency and blood stasis who visited our hospital were included and randomly divided into control group and experimental group, 45 cases in each group.The control group was treated with conventional Western medicine, and the experimental group was treated with Bushen Huoxue decoction on the basis of the control group. The course of treatment was 12 weeks. The therapeutic efficacy, the traditional Chinese medicine (TCM) syndrome scores, lipid levels, carotid intima-media thickness, pulse wave conduction velocity, maximum plaque area, safety indicators (blood routine, electrocardiogram, liver and kidney function) of the two groups were recorded and compared before and after treatment. The serum levels of ficolin (FCN)3, MBL-associated serine protease (MASP)-1, tumor necrosis factor (TNF)-α, interleukin (IL)-6, complement C3 and C4 were detected by enzyme-linked immunosorbent assay.
The total effective rate of the experimental group was higher than that of the control group (82.05% vs. 52.78%,P<0.05). After treatment, compared with the control group, the levels of total cholesterol, low density lipoprotein cholesterol, FCN3, MASP-1, complement C4, TNF-α in the experimental group were decreased (P<0.05), TCM syndrome scores and high density lipoprotein cholesterol level were increased (P<0.05), and pulse wave conduction velocity was decreased (P<0.05). During treatment, no significant adverse reactions or adverse events occurred in both groups.
Bushen Huoxue decoction can effectively improve the clinical symptoms of patients with CAS, improve the levels of blood lipids, inflammation and carotid ultrasound indexes, and the mechanism may be related to complement activation.
To evaluate the budget impact of the combination therapy of nivolumab and ipilimumab for the treatment of unresectable malignant pleural mesothelioma after its inclusion in the China's National Reimbuirsement Drug List (NRDL).
This study constructed a 5-year (2024—2028) budget impact analysis model from the perspective of the Chinese government health insurance authority to simulate the budget changes after the combination therapy of nivolumab and ipilimumab was included in the NRDL. The model analyzed factors such as the target population, drug market share, and treatment costs, comparing healthcare expenditures in scenarios with and without insurance coverage.One-way sensitivity analysis was performed to assess model robustness.
After inclusion in the NRDL, the incremental expenditure from 2024 to 2028 mainly stems from health insurance payment portion of drug costs, with a cumulative increase of 66.645 million yuan. However, the overall financial impact on the insurance fund remains minimal.Sensitivity analysis showed that drug prices, reimbursement rates, and insurance coverage rates were the key factors affecting budget changes.
Although the combination therapy of nivolumab and ipilimumab included in the NRDL will increase expenditure, the impact on the overall fund burden is limited.
To explore the effect of atosiban in the treatment of premature rupture of membranes in threatened preterm birth and its influence on placental blood perfusion and maternal and infant outcomes.
A total of 103 patients with premature rupture of membranes in threatened preterm birth in our hospital from September 2022 to August 2024 were selected and randomly divided into the study group (n=52, treated with atosiban) and the control group (n=51, treated with ritodrine hydrochloride). The clinical efficacy, placental blood perfusion, maternal and infant outcomes, symptom disappearance time, pregnancy prolongation time and the occurrence of adverse reactions were compared between the two groups.
After treatment, there was a significant difference in the total effective rate between the two groups (92.31% vs. 78.43%, P<0.05). The vascularization-blood flow index, flow index, placental vascularization index, neonatal asphyxia, fetal distress, amniotic fluid fecal contamination, incidence of maternal and infant adverse outcomes, and symptom disappearance time in the study group were all lower than those in the control group (P<0.05). The gestation time of the study group was longer than that of the control group (P<0.05). There was no significant difference in the occurrence of adverse reactions between the two groups (P>0.05).
The application of atosiban in premature rupture of membranes in threatened preterm birth has a better effect. It can assist in stabilizing placental blood perfusion, improve maternal and infant outcomes, and enhance pregnancy safety.
To explore the effect of bivalirudin combined with alprostadil on myocardial blood perfusion, hematological parameters and prognosis in patients with acute ST-segment elevation myocardial infarction (STEMI) after percutaneous coronary intervention (PCI).
A total of 294 patients with acute STEMI admitted to our hospital from January 2021 to November 2024 were selected and divided into control group A (treated with bivalirudin), control group B (treated with heparin+alprostadil), and observation group (treated with bivalirudin+alprostadil) according to the random number table method, with 98 cases in each group. The thrombolysis in myocardial infarction test (TIMI) blood flow classification, corrected TIMI flow frame count (CTFC) after surgery, and the rate of no-reflow phenomenon were compared before and 10 minutes after the operation among the three groups. The levels of serum interleukin (IL)-6, tumor necrosis factor (TNF)-α, C-reactive protein (CRP), and hematological parameters in the three groups before and 3 days after the operation were compared. The occurrence of major adverse cardiac event (MACE) within 30 days after PCI in the three groups was statistically analyzed.
After the operation, the incidence of TIMI grade 3 in the observation group was higher than that in the control group (P<0.05), and the incidences of CTFC and the rate of no-reflow phenomenon were lower than those in the control group (P<0.05). Three days after the operation, the levels of serum IL-6, TNF-α, CRP, the ratio of neutrophil/lymphocyte, neutrophils, mean platelet volume, and the ratio of mean platelet volume/lymphocyte in the three groups were lower than those before the operation, while lymphocytes were higher than those before the operation (P<0.05), and (P<0.05). At 30 days after the operation, the incidence of MACE in the observation group was lower than that in the control group (P<0.05).
Bivalirudin combined with alprostadil can reduce the inflammatory response in patients with acute STEMI undergoing PCI, improve myocardial blood perfusion, and reduce the occurrence of postoperative MACE.
To explore the clinical efficacy of modified Shenling Baizhu powder combined with mesalazine in the treatment of mild to moderate ulcerative colitis (UC) with spleen deficiency and dampness accumulation syndrome.
A total of 70 patients with mild to moderate UC with spleen deficiency and dampness accumulation syndrome admitted to the outpatient and ward of the department of spleen and stomach diseases of Jiangyin Hospital of Traditional Chinese Medicine and Jiangsu Province Hospital of Traditional Chinese Medicine from October 2023 to December 2024 were selected and divided into control group and treatment group according to the random number table method, with 35 cases in each group. The control group was treated with mesalazine, while the treatment group was treated with the modified formula of Shenling Baizhu Powder in addition to the treatment of control group. Both groups were treated for 24 weeks. The total effective rate, symptom score, colonoscopy mucosal lesion scores, and iron death related factors were compared between the two groups.
The total effective rate of the treatment group was better than that of the control group (94.29% vs. 82.86%, P<0.05). After treatment, the average symptom scores, colonic mucosal lesion scores and serum ferrous ion of the two groups decreased significantly (P<0.05). The levels of serum superoxide dismutase, glutathione and glutathione peroxidase 4 increased significantly (P<0.05). The improvement of diarrhea, abdominal distension, abdominal pain, limb drowsiness and anorexia in the treatment group were better than those in the control group (P<0.05). There was no statistically significant difference in the improvement of purulent bloody stool and colonic mucosal lesions between the two groups (P>0.05). No significant adverse reactions were observed in the two groups during treatment.
The modified Shenling Baizhu powder has a remarkable therapeutic effect on patients with mild to moderate UC with spleen deficiency and dampness accumulation syndrome, and it has good safety and high clinical application value.
To explore the efficacy and safety of Bawei Yijing capsules combined with western medicine in the treatment of systemic sclerosis (SSc) of Yang deficiency and cold coagulation type, as well as its influence on the levels of T lymphocyte subsets.
A total of 112 patients with SSc admitted to our hospital from November 2020 to October 2022 were selected and randomly divided into the conventional group and the combined group, with 56 cases in each group. The conventional group received basic western medical treatment, while the combined group was treated with Bawei Yijing capsules on the basis of the conventional group. Both groups were treated for 12 weeks continuously.The changes of skin hardness scores and the levels of T lymphocyte subsets before and after treatment were recorded in both groups, respectively. Meanwhile, the clinical efficacy and the occurrence of adverse reactions in the two groups were observed and compared.
After treatment, the total effective rate of the conventional group was lower than that of the combined group (75.00% vs. 94.64%, P<0.05). The skin hardness scores of both groups decreased compared with those before treatment (P<0.05), and the combined group showed a greater decrease (P<0.05). After treatment, the levels of CD3+, CD4+, and CD4+/CD8+ in both groups increased compared with before, while the positive rates of anti-SCL-70 antibody, anti-SSA/Ro-52kD antibody, pulmonary artery inner diameter, Furst's visceral score, and CD8+ level decreased compared with before (P<0.05). Moreover, the combined group showed greater increases in CD3+, CD4+, and CD4+/CD8+ levels (P<0.05), and greater decreases in the positive rates of anti-SCL-70 antibody, anti-SSA/Ro-52kD antibody, pulmonary artery inner diameter, Furst's visceral score, and CD8+ level (P<0.05). There was no significant difference in the incidence of adverse reactions between the groups during the treatment period (12.50% vs. 10.71%, P>0.05).
Bawei Yijing capsules combined with western medicine in the treatment of SSc can significantly improve the clinical efficacy, effectively alleviate the condition of patients, regulate the levels of T lymphocyte subsets, and has better safety.
To investigate the efficacy of metformin combined with nateglinide in the treatment of type 2 diabetes mellitus (T2DM) complicated with moderate to severe non-alcoholic fatty liver disease (NAFLD) and its influence on liver fibrosis.
A total of 120 patients with T2DM combined with moderate to severe NAFLD in Linquan County People's Hospital from November 2021 to December 2024 were selected and randomly divided into the observation group (metformin combined with nateglinide) and the control group (nateglinide), with 60 cases in each group. The treatment course for both groups was 4 weeks. The clinical efficacy, liver fibrosis, blood lipid, liver fat content, CT liver-spleen density ratio, chemokine, nesfatin-1 level and the incidence of adverse reactions were compared between the two groups.
After treatment, the total effective rate of treatment in the observation group was higher than that in the control group (93.33% vs. 78.33%, P<0.05). The levels of laminin, hyaluronic acid, type Ⅳ collagen, type Ⅲprocollagen, total cholesterol, triglycerides, low-density lipoprotein cholesterol, chemokine, nesfatin-1 and liver fat content in both groups were decreased compared with those before (P<0.05), and the levels in the observation group were lower than those in the control group (P<0.05). The levels of high-density lipoprotein cholesterol and densities of liver and spleen on CT scans in both groups increased compared with before (P<0.05), and the levels in the observation group were higher than those in the control group (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (6.67% vs. 1.67%, P>0.05).
For patients with T2DM combined with moderate to severe NAFLD, metformin combined with nateglinide can effectively improve liver fibrosis without increasing the risk of adverse reactions.
Based on the published literature and the data from completed clinical trials, the meta-analysis method was used to systematically evaluate the efficacy and safety of tenofovir and entecavir in the treatment of patients with chronic hepatitis B (CHB) cirrhosis.
PubMed, Web of Science, Embase, Clinicaltrials.gov, Cochrane library, China Biomedical Literature Service System database, China National Knowledge Infrastructure and Wanfang database were comprehensively searched. The search period was from the establishment date of the database to May 2024. The research data of tenofovir and entecavir in the treatment of patients with CHB cirrhosis were collected. The Cochrane systematic review method was used to screen the literature, evaluate the quality of the included literature, and extract the included characteristic information for meta-analysis. The outcome indicators included the negative conversion rate of hepatitis B virus (HBV)-DNA, the normalization rate of glutamic-pyruvic transaminase (GPT), the cumulative incidence of hepatocellular carcinoma (HCC), the cumulative mortality rate and the changes in estimated glomerular filtration rate (eGFR).
A total of 18 articles were included, involving 13 251 patients. The results showed that at 24 and 48 weeks of treatment, compared with entecavir, the negative conversion rate of HBV-DNA in the tenofovir group[odds ratio (OR)=0.84, 95% confidence interval (CI): 0.65—1.08, P=0.17; OR=0.98, 95%CI: 0.28—3.51, P=0.98] and the normalization rate of GPT (OR=1.12, 95%CI: 0.55—2.28, P=0.76; OR=1.35, 95%CI: 0.77—2.36, P=0.29) basically equivalent; Tenofovir can significantly reduce the incidence of cumulative HCC in patients (OR=0.57, 95%CI: 0.42—0.77, P=0.0003), However, there were no significant differences in cumulative mortality (OR=0.89, 95%CI: 0.44—1.83, P=0.76)and the change of eGFR changes (standardized mean difference: -3.02, 95%CI: -18.46—12.42, P=0.70)between the two groups.
Tenofovir and entecavir are basically equivalent in the treatment of CHB cirrhosis patients in terms of HBV-DNA negative conversion rate, eGPT normalization rate, cumulative mortality rate and renal function damage, while the former can significantly reduce the incidence of HCC in patients.
Proteolysis-targeting chimera (PROTAC) is a new technology for targeting protein degradation that has received great attention in the biomedical science community. PROTAC molecules can quickly and efficiently deplete target proteins by inducing degradation of target proteins using the ubiquitin-protease system, and can bind to substrates again to achieve multiple ubiquitination reactions, optimizing the dose dependence and drug resistance of traditional small molecules to a certain extent. However, this unique chemical structure and mechanism of action also brings many challenges to its in vivo and in vitro pharmacokinetic studies, mainly including poor solubility, poor permeability, poor oral absorption, and low bioavailability. Starting from the analysis of the physicochemical properties of PROTAC molecules, this article analyzed the pharmacokinetic characteristics and summarized the bioanalysis methods of such drugs. It also discussed the challenges and prospects of PROTAC technology, providing a reference for innovative research and breakthroughs in the field of PROTAC drugs.
Fondaparinux is the first artificially synthesized selective factor Ⅹa inhibitor of pentose. Due to its strong anticoagulant activity and certain safety, it is widely used in clinical practice. Especially for patients with low-molecular-weight heparin intolerance during pregnancy or those with heparin-induced thrombocytopenia, fondaparinux has become the preferred anticoagulant therapeutic drug. Fondaparinux has certain application value in obstetric related diseases such as venous thromboembolism, recurrent miscarriage and fetal growth restriction by inhibiting the activity of factor Ⅹa and not reacting with platelets. This article reviewed the clinical application of fondaparinux in the treatment of obstetrical-related diseases for clinical reference.